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Background: Public and patient involvement in the different stages of the health technology assessment (HTA)
process is increasingly encouraged. The selection of topics for assessment, which includes identifying and
prioritizing HTA questions, is a constant challenge for HTA agencies because the number of technologies requiring
an assessment exceeds the resources available. Public and patient involvement in these early stages of HTA could
make assessments more relevant and acceptable to them. Involving them in the development of the assessment
plan is also crucial to optimize their influence and impact on HTA research. The project objectives are: 1) setting up
interventions to promote patient participation in three stages of the HTA process: identification of HTA topics,
prioritization, and development of the assessment plan of the topic prioritized; and 2) assessing the impact of
patient participation on the relevance of the topics suggested, the prioritization process, and the assessment plan
from the point of view of patients and other groups involved in HTA.
Methods: Patients and their representatives living in the catchment area of the HTA Roundtable of Université
Laval’s Integrated University Health Network (covering six health regions of the Province of Quebec, Canada) will be
involved in the following HTA activities: 1) identification of potential HTA topics in the field of cancer; 2) revision of
vignettes developed to inform the prioritization of topics; 3) participation in deliberation sessions for prioritizing
HTA topics; and 4) development of the assessment plan of the topic prioritized. The research team will coordinate
the implementation of these activities and will evaluate the process and outcomes of patient involvement through
semi-structured interviews with representatives of the different stakeholder groups, structured observations, and
document analysis, mainly involving the comparison of votes and topics suggested by various stakeholder groups.
Discussion: This project is designed as an integrated approach to knowledge translation and will be conducted
through a close collaboration between researchers and knowledge users at all stages of the project. In response to
the needs expressed by HTA producers, the knowledge produced will be directly useful in guiding practices
regarding patient involvement in the early phases of HTA.
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Knowledge translationBackground
Public and patient involvement is recognized as an ef-
fective approach to improving the relevance of research,
increasing the value of scientific research without com-
promising its rigour, facilitating the implementation of
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unless otherwise stated.results [1,2]. In health technology assessment (HTA),
public and patient involvement is also considered as a
priority [3-8]. As direct beneficiaries of health services,
patients have a comprehensive knowledge of the impact
and the effects of a treatment or a technology on their
condition and on different aspects of their life [5,9].
Several authors have noted that decisions for selecting
technologies to assess should be more focused on the
values and needs of patients and the public [4,5,10]. The
selection of HTA topics which includes identifying tech-
nologies for assessment and prioritizing them, is part ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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number of technologies requiring an assessment signifi-
cantly exceeds the resources available, all HTA organiza-
tions face a problem of prioritization [11]. Some studies
have shown that patients’ priorities differ from those of
researchers and clinicians [2,12-15]. In the field of cancer,
Corner and Wright [12] have demonstrated that although
the biological aspects and those related to treatment were
considered important by patients, they rated the manage-
ment of practical, social and emotional issues as a higher
priority. The results echoed those of an earlier study con-
ducted by the U.S. National Cancer Institute in 1997 [13]
showing that although patients and their families were in
favour of cancer research, they felt that research often
more clearly served the interests of clinicians and re-
searchers than the priorities of the people directly affected
[13]. Including patients’ experiential knowledge in the se-
lection of HTA topics makes it possible to counterbalance
the potential biases brought by scientists or health profes-
sionals [16,17]. By involving patients and the public in the
identification and prioritization of HTA topics, assess-
ments are more likely to be relevant to them and adapted
to their needs [10,18].
A review of the different roles for patients and the
public in HTA shows that many agencies worldwide give
a role to patients and/or to the public in the identifica-
tion of assessment topics [10]. Most of the time, a down-
loadable electronic form is available to members of the
general public on the websites of HTA organizations,
thus enabling them to suggest assessment topics [10]. A
more proactive approach is also used by the program of
the National Institute for Health Research (NIHR) in the
United Kingdom [19-21]. This organization collaborates
with community groups and the James Lind Alliance, a
non-profit initiative funded by the NIHR, whose purpose
is to ensure that publicly funded research corresponds to
what matters to both patients and clinicians [22]. Commu-
nity groups are invited to submit suggestions for research
topics based on their experiences with particular health
conditions. In the United States, the Patient-Centered
Outcomes Research Institute also seeks questions from
patients through a website, social media and engagement
activities [23].
Regarding the prioritization of HTA topics, several agen-
cies across the world, including the Canadian Agency for
Drugs and Technologies in Health [24], are using similar
criteria: the burden of disease associated with the technol-
ogy, the potential clinical impact, the potential economic
repercussions, the impact on the funding budget of the
technology, the availability of evidence on the technology,
and the presence of alternatives [11]. Other context-specific
criteria are also considered, such as the expected level of
public interest, the potential controversy of the topic, the
accessibility and reimbursement of the technology, and thevariation in the rates of use [24]. However, there is little
knowledge available on how these criteria are actually used
to guide decisions in the selection of HTA topics [11].
Although several researchers consider that the prioritization
stage in HTA is value-laden and that a greater involve-
ment of stakeholders (including patients) would be im-
portant [10,25], patients are mostly excluded from this
stage in HTA [10], with some exceptions. One of these is
the HTA program of NIHR in the United Kingdom (UK),
which has established a whole infrastructure to support
public involvement in the identification and prioritization
of assessment topics [26,27]. Under this program, the pub-
lic contributes to prioritization in two ways: as reviewers
of vignettes that serve as the basis of discussion of the
prioritization committees and as members of the commit-
tees themselves [10,21]. Another experience of public in-
volvement in prioritization of HTA topics is that of the
Centers for Medicare and Medicaid Services in the USA,
which involve citizens in prioritization by offering them
the opportunity to comment upon potential issues that
are posted on their website [10].
The development of the assessment plan related to the
topic selected for HTA is also a stage at which it is par-
ticularly relevant to involve patients [28-30]. This stage,
which includes the identification of relevant issues, di-
mensions, measures and indicators related to the topic
selected, appears crucial to involve patients because it
enables an optimizing of their influence and impact on
the entire research initiative [4,5,29,30]. User involve-
ment at this stage can favour the relevance of research
questions to patients’ needs and ensure that the indicators
and measurement instruments actually reflect the dimen-
sions they want to include [14,20,28,30].
According to our conceptual framework of patient in-
volvement in HTA, three approaches concerning the
mechanisms of patient involvement could be distinguished:
active participation, consultation, and communication/
information (see Figure 1). Each of these approaches is
characterized by the level of patient involvement (participa-
tion as full partners, consultants, or recipients of informa-
tion) and by a set of corresponding techniques or methods.
Mitton and collaborators [31] have reviewed the vari-
ous techniques or methods of public involvement used
in the prioritization and allocation of resources. Despite
the lack of available evidence, their review suggests that
using deliberative methods may be associated with more
satisfactory results than using other methods that are
more consultative and characterized by a lower level of
public involvement [31]. Methods that involve face-to-
face interaction between participants from the public
and decision makers also generate greater participant
satisfaction, both in terms of process and results [31].
Furthermore, a study by Abelson [32] demonstrates that
the views of members of the public concerning priorities
Figure 1 Interventions to promote patient involvement in the early stages of the HTA process. Legend: Levels of patient involvement
according to the stages of the HTA process.
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to discuss the topics. According to this study, delibera-
tive methods could facilitate a more informed choice in
the prioritization of topics than methods such as ques-
tionnaires or individual interviews, where the opinion of
the public participants is requested only once and with-
out first being discussed.
Goal and setting of the project
This project builds upon a previous project entitled In-
volving patients in HTA activities at local level: a study
protocol based on the collaboration between researchers
and knowledge users [33] which allowed the involvement
of patients in the HTA process of assessing alternatives to
restraint and seclusion for hospitalized or institutionalized
adults. Based on the results of this experiment, this new
project will involve patients in HTA stages that have not
been considered in our previous work, namely the identifi-
cation and prioritization of HTA topics, and the develop-
ment of the assessment plan of the prioritized topic.
HTA producers need to find effective ways to incorp-
orate the perspective of patients in HTA structures andactivities [3,25]. This project has been developed in col-
laboration with the HTA Roundtable of the Integrated
University Health Network (IUHN) of Université Laval
(Quebec, Canada) that was set up in order to support
healthcare organizations throughout its territory in HTA
and knowledge transfer. This HTA roundtable recently ini-
tiated a consultation among its member organizations (in
a catchment area covering the whole of eastern Quebec)
whose results showed that assessments could better meet
local and regional needs. In Quebec, patients’ experience
regarding their choice of treatments, technologies, and
service modalities can differ depending on the region. Re-
gions with a university hospital have easier access to spe-
cialized and subspecialized care, and new technologies are
usually introduced earlier in these regions.
In continuity with our previous work, and to improve
the consideration of regional and local needs, the HTA
roundtable of this IUHN collaborated with researchers
from the project in order to involve patients with other
stakeholders from the six health regions of its catchment
area in the identification and prioritization of HTA topics
related to cancer. The theme of cancer was chosen by
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leading cause of death in Canada [34], and the entire
problem area raises a very broad array of questions and is-
sues that encompass the full range of services and health
policies, ranging from primary prevention, screening of tar-
get populations, access to healthcare services, and treat-
ment and expensive drugs, to palliative and end of life care.
Moreover, cancer represents a field in which new tech-
nologies, including drugs, evolve quickly, and for which
indications of current technologies also expand rapidly,
raising several relevant HTA questions.
The main study objectives are: 1) to set up interventions
promoting patient involvement in these regions in the se-
lection of HTA topics (identification and prioritization)
and in the development of the assessment plan of the
chosen subject, and 2) to assess the impacts of these inter-
ventions from the point of view of patients and other
groups involved in HTA. In this project, the term patient
refers to a person affected by a given technology (currently
or in the past), but also includes patient representatives
such as community groups.
Methods
Patients will be involved in four specific activities of the
HTA process (see Figure 1): 1) identification of HTA
topics; 2) revision of vignettes that will be developed to
inform the prioritization of the topics; 3) prioritization
of HTA topics; and 4) development of the assessment
plan. Different mechanisms of involvement will be used
according to the level of involvement (consultation and
direct participation) and the type of activity (topic sugges-
tion in a web form, vignette review, deliberative meetings
with other stakeholders to prioritize topics, HTA working
group). The research team will observe and evaluate the
process and outcomes associated with patient involvement
in all these activities. A participatory evaluation approach
will be used [35-38], involving stakeholders at all stages of
the research process (planning, design, data collection and
analysis, identification of outcomes, conclusions, recom-
mendations, and dissemination of results).
Identification of HTA topics
We will undertake consultations among various health-
care organizations and patient and community groups
from the IUHN territory in order to identify potential
topics for HTA in the field of cancer. With the collabor-
ation of the CEOs of the regional health and social services
agencies, the regional coordinator of oncology services,
and community organizations in cancer collaborating to
the project, we will contact healthcare professionals, man-
agers and community organizations to invite them to sug-
gest topics by way of an online or paper form. They will
also be invited to diffuse information about the project in
their community. We will provide instructions and specificexamples on the suggestion form. Participants will have to
indicate whether they are patients (current or past), close
relatives of patients, professionals, or healthcare managers
in order to allow for a consideration of the specificities of
each of these groups.
Filtration of topics and preparation of vignettes
Following the example of the NIHR HTA program in
the United Kingdom [20], we will then undertake a fil-
tration of the suggested topics. The topics will be exam-
ined by trained staff from the HTA unit of the Quebec
University Hospital Centre (QUHC) whose members will
check their relevance for an HTA program and whether
they have already been covered by a previous HTA pro-
ject. Moreover, we will set up a central prioritization com-
mittee assembling representatives of different categories
of stakeholders (managers, healthcare professionals and
patients) from the various regions covered by the project.
This committee will have to validate recommendations
made by the HTA unit. The six regions covered by the
study will be divided into three groups: university, periph-
eral and intermediary, and remote [39]. As a patient repre-
sentative will be recruited in each group of regions, at
least three patient representatives will participate in the
prioritization meeting in order to validate the final list
of topics.
Based on the UK experience [20,40], we will then pre-
pare short vignettes (less than one page) for each topic
in order to provide preliminary information on the re-
search question (technology, group of patients affected,
and context) and the potential effectiveness of the technol-
ogy. These vignettes will be sent to experts from relevant
fields for comments. At least one patient representative, se-
lected from those referred by patient organizations, will be
asked to review the vignettes. Reviewers will comment
upon the relevance and importance of the research and the
knowledge that could be produced [19].
Prioritization of HTA topics
We will organize deliberation sessions in each region cat-
egory (university, peripheral or intermediary, and remote)
with groups of approximately nine people – including
healthcare professionals, decision makers and patients –
to prioritize HTA topics. Based on the vignettes produced
at the previous stage, participants will be invited to discuss
the technologies presented. Two members of the project
team, including an HTA producer, will facilitate the delib-
eration sessions. Finally, each participant will vote indi-
vidually, and, in secret, will rate the proposed topics and
classify them in priority order. The votes of the partici-
pants will be compiled according to the category to which
they belong [41].
The central prioritization committee set up during the
filtration stage will meet again to establish, through a
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ity, as a means of identifying one priority topic that will be
evaluated as well as other important topics that could be
assessed in the future. The final decision as regards
accepting the proposed HTA topic will revert back to the
HTA Roundtable of Université Laval’s Integrated Univer-
sity Health Network, which could mandate the HTA unit
of the QUHC and its partners to conduct the assessment.
Following the recommendations of the UK HTA pro-
gram [19], a third of participants in the deliberation and
prioritization sessions must be patient representatives.
The recruitment of these representatives will begin with
a description of the work and the profile of the potential
participant, based on criteria developed by the NHS in
the UK [20,40]. The collaboration of cancer-related com-
munity organizations in this project will make it possible
to identify relevant candidates. To maximize the contri-
bution of patient representatives, we will try to recruit
individuals who are connected to peer networks and are
thus able to suggest a wide corpus of patients. We will
also try to respect balance regarding gender and age in
each of the groups.
The evaluation of public involvement in HTA prioritization
in the UK has demonstrated the importance of providing
dedicated staff and regular feedback to support this in-
volvement [19,26,27,40,42]. Therefore, patients will receive
training in HTA and evidence-informed healthcare before
the prioritization meeting [20]. A member of the research
team will also provide ongoing support for patient repre-
sentatives throughout the process.
Development of the assessment plan
For the last stage, a working group consisting of various
stakeholders, including patients, will be responsible for
the refining the topic selected and developing the assess-
ment plan. They will specify the research question, the
dimensions to be evaluated, and the strategies to imple-
ment in order to conduct this HTA, notably regarding
patient involvement in the next stages of the process.
The HTA process will then continue under the auspices
of the HTA unit of the QUHC, so this study will stop
following the development of the assessment plan, but
our previous collaborative projects with this HTA unit
will have laid the groundwork for pursuing patient in-
volvement at the next stages of the project.
Evaluation of processes and outcomes associated with
patient involvement
The research team will observe and evaluate the process
and outcomes associated with patient involvement through-
out the project using a participatory evaluation approach
[35-38]. Our team has already used this approach success-
fully in a previous project [33]. A workshop will be con-
ducted at the beginning of the project with knowledgeusers of the team to reach a consensus on the evaluation
objectives and questions. Data collection methods, indica-
tors of effects, outcomes and a data-analysis plan will also
be discussed, as well as the roles and responsibilities of
each team member. Such an approach is recognized as be-
ing the most effective for knowledge translation [43,44]. It
helps improve the outcomes of an intervention because
the results are consistent with practical information needs
of knowledge users and speak to the challenges they have
to face [45]. It also allows stakeholders to recognize them-
selves in the results and recommendations made, which
facilitates their use in decision making [45].
To assess interventions, we will consider the criteria re-
lated to the processes and those associated with the results
or impacts. We will partly apply the model proposed by
Rowe [46], which identifies nine criteria for assessing pa-
tient involvement: those related to the construction and
implementation of the process, i.e. 1) representativeness,
2) independence, 3) early involvement, 4) influence or im-
pact on decision making, 5) transparency; and those re-
lated to the process, including 6) accessibility of resources
to fulfill its role, 7) task definition, 8) structured decision
making and 9) cost-effectiveness. However, a subsequent
analysis of these criteria by Rowe and collaborators [47]
showed that although they have a certain validity, they
are not exhaustive, nor are they necessarily appropri-
ate for all involvement activities or all contexts. The
choice of outcome indicators, methods and analysis strat-
egies will be based on discussions with researchers and de-
cision makers, an approach recognized as being the most
effective for knowledge translation [43,44].
The evaluation of all interventions will be based mainly
on a qualitative approach, through in-depth interviews
and observations. The interviews will explore patients’
contributions and their influence on the process and re-
sults, as perceived by various stakeholders. Patient satis-
faction and perceptions regarding the final list of topics
and criteria that justified their choice will be of particular
interest to us. The interviews will also allow us to collect
suggestions to improve the process. The deliberation ses-
sions will be observed to analyze the course of discussions
and decision making. Document analysis will allow com-
paring the research priorities identified by patient repre-
sentatives, healthcare professionals, and managers.
The evaluation could contribute to improving current
knowledge on the impact of patient involvement in the
selection of HTA topics and on the factors influencing
this involvement. We will also pay particular attention
to the possibility of transposing the interventions imple-
mented to other HTA contexts. The proposed approach
is important in order to complete the knowledge transla-
tion cycle [48] since the knowledge produced through
this project will be useful for the development of future
interventions to support patient involvement in HTA.
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Ethics approval for the project has been received from
the Research Ethics Board of CHU de Québec (approved
on September 19, 2013; ethics number C13-08-1761).
Interviewees will be asked to complete a consent form
presenting the research objectives and information about
research implications.
Discussion
This project will help setting up interventions to pro-
mote patient participation in three stages of the HTA
process, and assessing the impacts of these interventions
on the relevance of the topic prioritized and the assess-
ment plan from the perspectives of patients and other
groups involved in the project. This study will comple-
ment our previous project, which enabled the involvement
of patients in a specific HTA on alternative measures to
restraint and seclusion [33]. In that particular project, in-
volvement of patients in the stages of identification,
prioritization, and development of the assessment plan
was not possible due to the timing of the research. Based
on the positive results of this experience, the present pro-
ject will make it possible to involve patients in the early
stages of HTA that have not been considered in our previ-
ous work.
Despite various initiatives to involve patients in the
HTA stages, assessments of the impact of these initia-
tives are rather sparse and anecdotal [10]. Evidence on
the effectiveness of public participation (including pa-
tients) in HTA is only beginning to emerge [14,40]. The
project will therefore allow us not only to apply know-
ledge from other studies in the Canadian context, but
also to evaluate proposed interventions, and thus will
provide essential knowledge on the effectiveness of the
involvement strategies put in place by paying particular
attention to the involvement process, including its im-
plementation and follow-up, while considering the views
of different stakeholders. If we do not want this involve-
ment to remain anecdotal, it is important for knowledge
users to rely on evidence to develop strategies for patient
involvement in HTA decision making [49].
Knowledge translation activities
In this project, knowledge translation is adapted to the
local context and to knowledge users’ needs because of
the collaborative approach adopted. One of the strategies
will consist in presenting progress reports and results
periodically to all stakeholders involved in the project.
We will also communicate the results of each phase to
stakeholders from the regions concerned through the
participation of researchers from the team in the HTA
Roundtable of the IUHN. Targeted presentations will
provide a forum for discussing the research process, data
analysis, and interpretation of results. Presentations willalso be made to provide information about the process
of the project and present its results to a wider audience
(Ministry of Health and Social Services, Quebec National
Institute of Public Health, Health and Welfare Commission,
as well as relevant patient organizations). This will facili-
tate a consideration of the potential for dissemination
and the applicability of the interventions to other or-
ganizations interested in HTA. These presentations will
be integrated into the regular training activities of the
organizations concerned. A brief questionnaire will be
distributed to participants after each meeting to assess
the relevance of these meetings, the understanding of
key messages, and the intention to apply them in
their practice.
The research team will work with the HTA Roundtable
of the IUHN to share and disseminate lessons learned with
the Quebec community of practice in HTA, and other pro-
vincial, national and international HTA organizations. To
adapt the dissemination of results to different audiences,
representatives of all groups involved in the project will
participate in the dissemination process. Collaborations
with patient groups and community organizations will
also facilitate the sharing of results directly with patients.
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